Kyrgyzfarmatsiya, the state enterprise under the Ministry of Health in Kyrgyzstan, has successfully concluded contracts with seven manufacturers of medicines, resulting in substantial savings of over $1.1mn in budget funds.
The state enterprise continues its efforts to finalize more contracts with other pharmaceutical manufacturers. Recently, Gulmira Shakirova, the Director of Kyrgyzfarmatsiya, held a meeting with representatives from PSK Pharma, a Russian plant specializing in the production of medicines. During the meeting, PSK Pharma proposed a flexible payment system, demonstrating its commitment to collaborating with Kyrgyzfarmatsiya.
Director Shakirova emphasized that one of the primary objectives of Kyrgyzfarmatsiya is to provide high-quality medicines to state healthcare organizations at affordable prices. Additionally, the state enterprise has been granted the authority to directly enter into agreements for the supply of medicines and medical products without having to undergo the tender process.
“We offer partners who have provided good discounts on medicines to take advantage of special conditions — to conclude long-term contracts for the supply of medicines to healthcare organizations,” stated Gulmira Shakirova.
The establishment of Kyrgyzfarmatsiya as a state enterprise under the Ministry of Health occurred on March 31. Since its inception, the organization has been actively working towards achieving its goal of ensuring the availability of quality medications for the people of Kyrgyzstan while also optimizing budget expenditures.
With the successful conclusion of seven contracts and the resulting savings of over $1.1mn, Kyrgyzfarmatsiya has made a significant step towards fulfilling its mission. By forging partnerships with reputable pharmaceutical manufacturers and promoting cost-effective procurement strategies, the state enterprise aims to improve the accessibility of essential medicines for healthcare institutions across the country, ultimately benefiting the well-being of the Kyrgyz population.
Comments (0)